146 related articles for article (PubMed ID: 12818809)
1. Physical and thermal characterisation of Precirol and Compritol as lipophilic glycerides used for the preparation of controlled-release matrix pellets.
Hamdani J; Moës AJ; Amighi K
Int J Pharm; 2003 Jul; 260(1):47-57. PubMed ID: 12818809
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of prolonged release pellets obtained by the melt pelletization process.
Hamdani J; Moës AJ; Amighi K
Int J Pharm; 2002 Oct; 245(1-2):167-77. PubMed ID: 12270253
[TBL] [Abstract][Full Text] [Related]
3. Influence of melting and rheological properties of fatty binders on the melt granulation process in a high-shear mixer.
Evrard B; Amighi K; Beten D; Delattre L; Moës AJ
Drug Dev Ind Pharm; 1999 Nov; 25(11):1177-84. PubMed ID: 10596355
[TBL] [Abstract][Full Text] [Related]
4. Development and in vitro evaluation of a novel floating multiple unit dosage form obtained by melt pelletization.
Hamdani J; Moës AJ; Amighi K
Int J Pharm; 2006 Sep; 322(1-2):96-103. PubMed ID: 16824707
[TBL] [Abstract][Full Text] [Related]
5. Preparation of lipid aspirin sustained-release pellets by solvent-free extrusion/spheronization and an investigation of their stability.
Yan X; He H; Meng J; Zhang C; Hong M; Tang X
Drug Dev Ind Pharm; 2012 Oct; 38(10):1221-9. PubMed ID: 22713120
[TBL] [Abstract][Full Text] [Related]
6. Lipids bearing extruded-spheronized pellets for extended release of poorly soluble antiemetic agent-Meclizine HCl.
Qazi F; Shoaib MH; Yousuf RI; Nasiri MI; Ahmed K; Ahmad M
Lipids Health Dis; 2017 Apr; 16(1):75. PubMed ID: 28403892
[TBL] [Abstract][Full Text] [Related]
7. Structural and thermal characterization of glyceryl behenate by X-ray diffraction coupled to differential calorimetry and infrared spectroscopy.
Brubach JB; Jannin V; Mahler B; Bourgaux C; Lessieur P; Roy P; Ollivon M
Int J Pharm; 2007 May; 336(2):248-56. PubMed ID: 17207945
[TBL] [Abstract][Full Text] [Related]
8. Influence of poloxamers on the dissolution performance and stability of controlled-release formulations containing Precirol ATO 5.
Jannin V; Pochard E; Chambin O
Int J Pharm; 2006 Feb; 309(1-2):6-15. PubMed ID: 16376034
[TBL] [Abstract][Full Text] [Related]
9. Technology of stable, prolonged-release eye-drops containing Cyclosporine A, distributed between lipid matrix and surface of the solid lipid microspheres (SLM).
Wolska E; Sznitowska M
Int J Pharm; 2013 Jan; 441(1-2):449-57. PubMed ID: 23164704
[TBL] [Abstract][Full Text] [Related]
10. Preparation and In Vitro-In Vivo Evaluation of Sustained-Release Matrix Pellets of Capsaicin to Enhance the Oral Bioavailability.
Zhang Y; Huang Z; Omari-Siaw E; Lu S; Zhu Y; Jiang D; Wang M; Yu J; Xu X; Zhang W
AAPS PharmSciTech; 2016 Apr; 17(2):339-49. PubMed ID: 26127010
[TBL] [Abstract][Full Text] [Related]
11. Solid lipid extrusion of sustained release dosage forms.
Reitz C; Kleinebudde P
Eur J Pharm Biopharm; 2007 Sep; 67(2):440-8. PubMed ID: 17481868
[TBL] [Abstract][Full Text] [Related]
12. Study of petrolatum structure: Explaining its variable rheological behavior.
van Heugten AJP; Landman J; Petukhov AV; Vromans H
Int J Pharm; 2018 Apr; 540(1-2):178-184. PubMed ID: 29452154
[TBL] [Abstract][Full Text] [Related]
13. Novel approach for overcoming the stability challenges of lipid-based excipients. Part 2: Application of polyglycerol esters of fatty acids as hot melt coating excipients.
Salar-Behzadi S; Corzo C; Gomes Lopes D; Meindl C; Lochmann D; Reyer S
Eur J Pharm Biopharm; 2020 Mar; 148():107-117. PubMed ID: 31982575
[TBL] [Abstract][Full Text] [Related]
14. Development of sustained-release lipophilic calcium stearate pellets via hot melt extrusion.
Roblegg E; Jäger E; Hodzic A; Koscher G; Mohr S; Zimmer A; Khinast J
Eur J Pharm Biopharm; 2011 Nov; 79(3):635-45. PubMed ID: 21801834
[TBL] [Abstract][Full Text] [Related]
15. A dual strategy to improve psychotic patients' compliance using sustained release quetiapine oral disintegrating tablets.
Refaat A; Sokar M; Ismail F; Boraei N
Acta Pharm; 2016 Dec; 66(4):515-532. PubMed ID: 27749256
[TBL] [Abstract][Full Text] [Related]
16. Optimizing a wet granulation process to obtain high-dose sustained-release tablets with Compritol 888 ATO.
Rosiaux Y; Girard JM; Desvignes F; Miolane C; Marchaud D
Drug Dev Ind Pharm; 2015; 41(10):1738-44. PubMed ID: 25652358
[TBL] [Abstract][Full Text] [Related]
17. Crystal growth formation in melt extrudates.
Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
[TBL] [Abstract][Full Text] [Related]
18. Controlled release tablet formulation containing natural Δ(9)-tetrahydrocannabinol.
Punyamurthula NS; Hingorani T; Adelli G; Gul W; ElSohly MA; Repka MA; Majumdar S
Drug Dev Ind Pharm; 2016; 42(7):1158-64. PubMed ID: 26585693
[TBL] [Abstract][Full Text] [Related]
19. Wax-based sustained release matrix pellets prepared by a novel freeze pelletization technique II. In vitro drug release studies and release mechanisms.
Cheboyina S; Wyandt CM
Int J Pharm; 2008 Jul; 359(1-2):167-73. PubMed ID: 18495391
[TBL] [Abstract][Full Text] [Related]
20. Exploring the possible relationship between the drug release of Compritol®-containing tablets and its polymorph forms using micro X-ray diffraction.
Jannin V; Rosiaux Y; Doucet J
J Control Release; 2015 Jan; 197():158-64. PubMed ID: 25445699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
